Drugs / Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06757881 | Jan → Aug 2025 overdue | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06757881 ↗ |
| Modality | Cell therapy | “Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells” NCT06757881 ↗ |
| Target | IL1RAP | “IL1RAP-targeting Chimeric Antigen Receptor T Cells” NCT06757881 ↗ |